Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. AGTC's lead product candidates are designed to address the underlying genetic defects in inherited retinal diseases, which cause progressive blindness, and inherited rare diseases of the central nervous system that affect both adults and children. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), and one named CNS program for a rare disease, alpha-1 antitrypsin (A1AT) deficiency. The Company's XLRS, XLRP and Achromatopsia programs, which are partnered with Biogen, are in Phase 1/2 clinical trials. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.